# Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

> **NCT06952842** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chigenovo Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** ZVS203e

## Key facts

- **NCT ID:** NCT06952842
- **Lead sponsor:** Chigenovo Co., Ltd
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-18
- **Primary completion:** 2030-06-18
- **Final completion:** 2045-06-18
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952842, "Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06952842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*